A key role for EZH2 in epigenetic silencing of HOX genes in mantle cell lymphoma
Published 2013 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
A key role for EZH2 in epigenetic silencing of HOX genes in mantle cell lymphoma
Authors
Keywords
-
Journal
Epigenetics
Volume 8, Issue 12, Pages 1280-1288
Publisher
Informa UK Limited
Online
2013-10-10
DOI
10.4161/epi.26546
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- EZH2 Is Required for Germinal Center Formation and Somatic EZH2 Mutations Promote Lymphoid Transformation
- (2013) Wendy Béguelin et al. CANCER CELL
- Mantle cell lymphoma displays a homogenous methylation profile: A comparative analysis with chronic lymphocytic leukemia
- (2012) Anna Margrét Halldórsdóttir et al. AMERICAN JOURNAL OF HEMATOLOGY
- Coordinated Silencing of MYC-Mediated miR-29 by HDAC3 and EZH2 as a Therapeutic Target of Histone Modification in Aggressive B-Cell Lymphomas
- (2012) Xinwei Zhang et al. CANCER CELL
- Superior Efficacy of a Combined Epigenetic Therapy against Human Mantle Cell Lymphoma Cells
- (2012) W. Fiskus et al. CLINICAL CANCER RESEARCH
- EZH2 inhibition as a therapeutic strategy for lymphoma with EZH2-activating mutations
- (2012) Michael T. McCabe et al. NATURE
- Lymphoblastoid cell line with B1 cell characteristics established from a chronic lymphocytic leukemia clone by in vitro EBV infection
- (2012) Anders Rosén et al. OncoImmunology
- Enhancer of zeste homolog 2: A potential target for tumor therapy
- (2011) Yongtao Xiao INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY
- Quantitative methylation analysis of HOXA3, 7, 9, and 10 genes in glioma: association with tumor WHO grade and clinical outcome
- (2011) Angela Di Vinci et al. JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
- microRNA expression profile and identification of miR-29 as a prognostic marker and pathogenetic factor by targeting CDK6 in mantle cell lymphoma
- (2010) J.-J. Zhao et al. BLOOD
- Epigenetic regulation of miR-196b expression in gastric cancer
- (2010) Kuo-Wang Tsai et al. GENES CHROMOSOMES & CANCER
- Expression of miR-196b is not exclusively MLL-driven but is especially linked to activation of HOXA genes in pediatric acute lymphoblastic leukemia
- (2010) D. Schotte et al. HAEMATOLOGICA
- Polycomb repressor complex 2 regulates HOXA9 and HOXA10, activating ID2 in NK/T-cell lines
- (2010) Stefan Nagel et al. Molecular Cancer
- TNF Inhibits Notch-1 in Skeletal Muscle Cells by Ezh2 and DNA Methylation Mediated Repression: Implications in Duchenne Muscular Dystrophy
- (2010) Swarnali Acharyya et al. PLoS One
- Polycomb Target Genes Are Silenced in Multiple Myeloma
- (2010) Antonia Kalushkova et al. PLoS One
- Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells
- (2009) W. Fiskus et al. BLOOD
- Differential genome-wide array-based methylation profiles in prognostic subsets of chronic lymphocytic leukemia
- (2009) M. Kanduri et al. BLOOD
- Guidelines for the diagnosis and treatment of chronic lymphocytic leukemia: a report from the International Workshop on Chronic Lymphocytic Leukemia updating the National Cancer Institute-Working Group 1996 guidelines
- (2008) M. Hallek et al. BLOOD
- Five-Gene Model to Predict Survival in Mantle-Cell Lymphoma Using Frozen or Formalin-Fixed, Paraffin-Embedded Tissue
- (2008) Elena Hartmann et al. JOURNAL OF CLINICAL ONCOLOGY
- Roles of the EZH2 histone methyltransferase in cancer epigenetics
- (2008) Jeffrey A. Simon et al. MUTATION RESEARCH-FUNDAMENTAL AND MOLECULAR MECHANISMS OF MUTAGENESIS
- Cooperation between EZH2, NSPc1-mediated histone H2A ubiquitination and Dnmt1 in HOX gene silencing
- (2008) Xudong Wu et al. NUCLEIC ACIDS RESEARCH
Create your own webinar
Interested in hosting your own webinar? Check the schedule and propose your idea to the Peeref Content Team.
Create NowAsk a Question. Answer a Question.
Quickly pose questions to the entire community. Debate answers and get clarity on the most important issues facing researchers.
Get Started